Last deal

$40M

Amount

Post-IPO Equity

Stage

18.02.2021

Date

3

all rounds

$159.9M

Total amount

date founded

Financing round

General

About Company
Protalix develops and manufactures therapeutic proteins using ProCellEx plant cell-based system.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1994

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Protalix focuses on developing and commercializing novel and biosimilar proteins for genetic disorders and inflammatory diseases. Their flagship product, ELELYSO, is the first FDA-approved plant cell-based recombinant therapeutic protein. Protalix has partnered with Pfizer for global development and commercialization of ELELYSO, except in Israel where Protalix retains full rights. The company has also submitted marketing applications for taliglucerase alfa in Europe, Israel, Brazil, and Australia. Protalix generates revenue from sales of taliglucerase alfa in Brazil and drug substance sales to Pfizer.
Contacts
Similar Companies
1000
Calixa Therapeutics

Calixa Therapeutics

Calixa Therapeutics is a biopharmaceutical company focused on developing a novel cephalosporin to combat multi-drug resistant organisms.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

San Mateo, CA, USA

total rounds

1
BaroFold

BaroFold

BaroFold is a biopharmaceutical company focused on developing protein therapeutics for immunology indications.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Biopharma, Therapeutics

Location

Aurora, CO, USA

total rounds

4

total raised

$17.4M
Sutro Biopharma

Sutro Biopharma

Sutro Biopharma develops protein therapeutics using its proprietary XpressCF platform to treat cancer and autoimmune disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

12

total raised

$636.61M
Coherus Biosciences

Coherus Biosciences

Coherus Biosciences develops and sells biologic therapeutics for oncology and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Redwood City, CA, USA

total rounds

16

total raised

$1.27B

Financials

Funding Rounds
9
3

Number of Funding Rounds

$159.9M

Money Raised

Their latest funding was raised on 18.02.2021. Their latest investor Cybele Holdings. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
18.02.2021
1
$40M
12.03.2020
6
$43.7M
14.10.2015
1
$10M
Pfizer

Pfizer

Pfizer is a company that provides safe, effective, and affordable medicines and healthcare services.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

New York, NY, USA

total rounds

1

total raised

$31B

count Of Investments

39

count Of Exists

2
Co-Investors
Investors
11
4

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
No
Post-IPO Equity
Yes
Series C
Cybele Holdings

Cybele Holdings

Cybele Group offers consulting, financial services, investment banking, brokerage, and asset management.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

Ramat Gan, Israel

count Of Investments

127

count Of Exists

13
Office of the Chief Scientist

Office of the Chief Scientist

The represented Corporate Investor is a venture capital firm based in Tel Aviv.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Tel Aviv-Yafo, Israel

count Of Investments

33

count Of Exists

3
Tamares

Tamares

Tamares is a private investment group with diverse interests in real estate, technology, manufacturing, leisure, and media.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital

Location

Gibsland, LA 71028, USA

count Of Investments

12

count Of Exists

2

People

Founders
1

Yoseph Shaaltiel

Dr. Shaaltiel founded Protalix Ltd. in 1993 and has served as our Vice President, Research and Development since December 31, 2006. Prior to establishing Protalix, Dr. Shaaltiel was a Research Associate at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey. He has co-authored over 40 articles and abstracts on plant biochemistry and holds seven patents. Dr. Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.

current job

Protalix BioTherapeutics
Protalix BioTherapeutics

organization founded

1

Yoseph Shaaltiel

Employee Profiles
6
Dror Bashan

Dror Bashan

President & CEO

Yoseph Shaaltiel

Founder & Executive Vice President, Research and Development

David Aviezer

President and CEO

Yaron Naos

SVP, Operations

Activity

Recent News
6
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week